Form 4: Cargo Therapeutics Executive Acquires 60,000 Shares of Common Stock

Shishir Gadam, Chief Technical Officer of Cargo Therapeutics, acquired 60,000 shares of common stock on March 14, 2025, through restricted stock units.

Summary

• On March 14, 2025, Shishir Gadam, the Chief Technical Officer of Cargo Therapeutics, acquired 60,000 shares of common stock.
• The acquisition was made through restricted stock units (RSUs), where each RSU entitles Gadam to one share of common stock upon vesting.
• The RSUs vest in installments, with 1/16th vesting each quarter starting from January 1, 2025.
• Full vesting of the RSUs will occur on the fourth anniversary of the Vesting Commencement Date.
• Following the transaction, Gadam beneficially owns 89,480 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by an executive, neither particularly positive nor negative.

Positives

• The acquisition of shares by a key executive could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the holdings of key personnel.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding executive compensation and ownership.

Key Dates